Konruns(SH:603590) Xin Lang Cai Jing·2026-02-04 05:29Group 1 - The core viewpoint of the news is that Kangchen Pharmaceutical has seen a stock price increase of 5.08%, reaching 41.40 yuan per share, with a total market capitalization of 6.583 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, focuses on innovative drug research and development, with its main business revenue composition being 70.77% from Suling, 29.15% from Salmon Calcitonin (Mikayxin), and 0.09% from other sources [1] - The trading volume for Kangchen Pharmaceutical was 1.45 billion yuan, with a turnover rate of 2.25% [1] Group 2 - Huabao Fund has a significant holding in Kangchen Pharmaceutical, with its Huabao New Vitality Mixed C Fund (003154) holding 14,100 shares, accounting for 1.09% of the fund's net value, making it the sixth-largest holding [2] - The Huabao New Vitality Mixed C Fund has a total scale of 51.4002 million yuan and has achieved a year-to-date return of 6.53% [2] - The fund manager, Yu Yinyou, has a tenure of 3 years and 216 days, with the best fund return during this period being 52.34% [2]